Skip to main content

Advertisement

Table 8 Drug-related adverse events in metastatic renal cell carcinoma patients with post-treatment hypoalbuminemia and normal serum albumin level

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Drug-related adverse event Post-treatment hypoalbuminemia (albumin level < 36.4 g/L) group Normal serum albumin level (albumin level ≥36.4 g/L) group P value*
Any grade Grade 1–2 Grade 3–4 Any grade Grade 1–2 Grade 3–4
Hand–foot syndrome 22 (57.9) 22 (57.9) 0 (0.0) 99 (67.8) 90 (61.6) 9 (6.2) 0.251
Diarrhea 20 (52.6) 20 (52.6) 0 (0.0) 78 (53.4) 73 (50.0) 5 (3.4) 0.930
Nausea 20 (52.6) 20 (52.6) 0 (0.0) 54 (37.0) 54 (37.0) 0 (0.0) 0.080
Fatigue 17 (44.7) 17 (44.7) 0 (0.0) 61 (41.8) 61 (41.8) 0 (0.0) 0.743
Hypertension 17 (44.7) 17 (44.7) 0 (0.0) 42 (28.7) 38 (26.0) 4 (2.7) 0.060
Anemia 12 (29.6) 10 (26.3) 2 (5.3) 16 (11.0) 16 (11.0) 0 (0.0) 0.002
Thrombocytopenia 11 (29.0) 11 (29.0) 0 (0.0) 29 (19.9) 27 (18.5) 2 (1.4) 0.227
Leukocytopenia 8 (21.1) 8 (21.1) 0 (0.0) 29 (19.9) 27 (18.5) 2 (1.4) 0.871
Elevation of ALT 8 (21.0) 8 (21.1) 0 (0.0) 16 (11.0) 15 (10.3) 1 (0.7) 0.170
Alopecia 6 (15.8) 6 (15.8) 0 (0.0) 11 (7.5) 11 (7.5) 0 (0.0) 0.211
Hypothyroidism 3 (7.9) 3 (7.9) 0 (0.0) 13 (8.9) 13 (8.9) 0 (0.0) 1.000
  1. All data are presented as the number of patients followed by percentage in parentheses
  2. ALT, alanine aminotransferase
  3. * Grade 1–2 and grade 3–4 adverse events were combined in P value calculation